Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-1140675 in healthy adults. The trial aims to assess ...
Please provide your email address to receive an email when new articles are posted on . Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors ...
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment VMAT2 occupancy is a key ...
Neurocrine Biosciences Inc. has disclosed vesicular monoamine transporter 2 (VMAT2) inhibitors reported to be useful for the treatment of neurological and psychiatric disorders, among others.
A 36-year-old man with a diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), was referred to a psychiatry clinic for severe, ...
Proteins such as VMAT2 and VGAT are called vesicular transporters, because they pump neurotransmitters from the neuronal cytoplasm into vesicles that are then unloaded at the synaptic junction between ...
announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study ...
Please provide your email address to receive an email when new articles are posted on . The investigators aimed to examine the efficacy of TD pharmacologic treatments by searching the PubMed database ...
SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results